Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
about
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@en
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@nl
type
label
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@en
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@nl
prefLabel
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@en
Randomized phase 2 study of ti ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Randomized phase 2 study of ti ...... ced non-small cell lung cancer
@en
P2093
Bruno R Bastos
Chao Huang
Deepa S Subramaniam
Heather A Wakelee
Joan H Schiller
Joel W Neal
Julia Kazakin
Julie R Brahmer
Keisuke Shirai
P2860
P356
10.1016/J.LUNGCAN.2018.01.010
P577
2018-02-03T00:00:00Z